European Medicines Agency warns of diabetics’ risk amid Ozempic shortage
Off-label treatment of obesity with Novo Nordisk’s Ozempic is putting patients with diabetes at risk when shortages arise, and Europe’s drug authority is now asking doctors to prioritize.
By Janice Kew, bloomberg
The increasing use of diabetes drug Ozempic as a weight-loss treatment prompted the European Medicines Agency (EMA) to urge doctors to prioritize the injection made by Novo Nordisk A/S for diabetics, who may be at risk if they don’t get it.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Wegovy exponents did not disclose payments from Novo Nordisk
For subscribers
New diabetes drugs changing treatment in the US
For subscribers
Demand for Novo Nordisk's Wegovy accelerating
For subscribers
.jpg&w=384&q=75)
